<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Science and Innovations in Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Science and Innovations in Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Наука и инновации в медицине</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2500-1388</issn><issn publication-format="electronic">2618-754X</issn><publisher><publisher-name xml:lang="en">FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">96118</article-id><article-id pub-id-type="doi">10.35693/2500-1388-2021-6-4-55-58</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Cardiology</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Кардиология</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">ST2 in heart failure with reduced and mid-range ejection fraction: clinical and instrumental relationships and prognostic value</article-title><trans-title-group xml:lang="ru"><trans-title>ST2 при сердечной недостаточности со сниженной и промежуточной фракцией выброса: клинико-инструментальные взаимосвязи и прогностическое значение</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8763-9629</contrib-id><name-alternatives><name xml:lang="en"><surname>Kompanets</surname><given-names>Natalya V.</given-names></name><name xml:lang="ru"><surname>Компанец</surname><given-names>Наталия Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Assistant professor, Chair of Introduction to internal medicine</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент, ассистент кафедры пропедевтической терапии</p></bio><email>rogdestvenskaja@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5673-7958</contrib-id><name-alternatives><name xml:lang="en"><surname>Aidumova</surname><given-names>Olesya Yu.</given-names></name><name xml:lang="ru"><surname>Айдумова</surname><given-names>Олеся Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>cardiologist, senior laboratory assistant of the Chair of Introduction to internal medicine</p></bio><bio xml:lang="ru"><p>врач-кардиолог, старший лаборант кафедры пропедевтической терапии</p></bio><email>volga.rassvet@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0387-8356</contrib-id><name-alternatives><name xml:lang="en"><surname>Shchukin</surname><given-names>Yurii V.</given-names></name><name xml:lang="ru"><surname>Щукин</surname><given-names>Юрий В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Professor, Head of the Chair of Introduction to internal medicine</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, заведующий кафедрой пропедевтической терапии</p></bio><email>yu.v.schukin@samsmu.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Samara State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2021</year></pub-date><volume>6</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>55</fpage><lpage>58</lpage><history><date date-type="received" iso-8601-date="2022-01-08"><day>08</day><month>01</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-01-08"><day>08</day><month>01</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Kompanets N.V., Aidumova O.Y., Shchukin Y.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Компанец Н.В., Айдумова О.Ю., Щукин Ю.В.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Kompanets N.V., Aidumova O.Y., Shchukin Y.V.</copyright-holder><copyright-holder xml:lang="ru">Компанец Н.В., Айдумова О.Ю., Щукин Ю.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://innoscience.ru/2500-1388/article/view/96118">https://innoscience.ru/2500-1388/article/view/96118</self-uri><abstract xml:lang="en"><p><bold>Objectives</bold> – to determine the clinical and instrumental relationships and prognostic value of sST2 in chronic heart failure with reduced and mid-range ejection fraction of ischemic etiology.</p> <p><bold>Material and methods.</bold> The study included examination of 64 patients with heart failure with left ventricular ejection fraction &lt;50% and myocardial infarction in medical history; mean age 55.7 ± 8.7 years.</p> <p><bold>Results.</bold> Higher concentrations sST2 was determined with an increased end-diastolic volume, left ventricular aneurysm, left main coronary artery stenosis, glomerular filtration rate &lt;90 ml/min/1.73 m<sup>2</sup> (p &lt; 0.05 for all ). The study confirmed a high predictive significance of increased levels sST2 (p = 0.001); the area under the curve was 0.772; the odds ratio for an adverse outcome with sST2 ≥ 35 ng/ml was 3.93.</p> <p><bold>Conclusion.</bold> sST2 is a predictor of adverse outcome during the first year of follow-up in patients with heart failure with reduced and mid-range ejection fraction of ischemic etiology.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель</bold> – определить клинико-инструментальные взаимосвязи и прогностическое значение sST2 при хронической сердечной недостаточности со сниженной и промежуточной фракцией выброса ишемической этиологии.</p> <p><bold>Материал и методы.</bold> Обследовано 64 пациента с сердечной недостаточностью с фракцией выброса левого желудочка &lt;50% и инфарктом миокарда в анамнезе; средний возраст составил 55,7±8,7 года.</p> <p><bold>Результаты. </bold>Определено более высокое содержание sST2 при увеличенном конечно-диастолическом объеме, аневризме левого желудочка, стенозе ствола левой коронарной артерии, скорости клубочковой фильтрации &lt;90 мл/мин/1,73м<sup>2</sup> (для всех p &lt;0,05). Подтверждена прогностическая значимость повышенного уровня sST2 в исследуемой когорте (p =0,001); площадь под кривой составила 0,772; отношение шансов неблагоприятного исхода при sST2 ≥35 нг/мл – 3,93.</p> <p><bold>Заключение.</bold> У пациентов с сердечной недостаточностью со сниженной и промежуточной фракцией выброса ишемической этиологии sST2 является предиктором неблагоприятного исхода в течение ближайшего года наблюдения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>ST2</kwd><kwd>heart failure</kwd><kwd>prognosis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ST2</kwd><kwd>сердечная недостаточность</kwd><kwd>прогноз</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clinica Chimica Acta. 2015;443:57–70. doi: 10.1016/j.cca.2014.09.021</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Khoreva MV, Gankovskaya LV, Smirnova AD, et al. IL-33/ST2: new biomarker and therapeutic target. Russian Journal of Immunology. 2016;19(1):16–24. (In Russ.). [Хорева М.В., Ганковская Л.В., Смирнова А.Д. и др. IL-33/ST2: Новый биомаркер и терапевтическая мишень. Российский иммунологический журнал. 2016;19(1):16–24].</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. The American Journal of Cardiology. 2015;115(7):3B–7B. doi: 10.1016/j.amjcard.2015.01.034</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>McCarthy CP, Januzzi JL. Soluble ST2 in Heart Failure. Heart Failure Clinics. 2018;14(1):41–48. doi: 10.1016/j.hfc.2017.08.005</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Kohli P, Bonaca MP, Kakkar R, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clinical Chemistry. 2012;58(1):257–266. doi: 10.1373/clinchem.2011.173369</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Chow SL, Maisel AS, Anand I, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the American Heart Association. Circulation. 2017;135(22):e1054-e1091. doi: 10.1161/CIR.0000000000000490</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bayes-Genis A, Januzzi JL, Gaggin HK, et al. ST2 pathogenetic profile in ambulatory heart failure patients. Journal of Cardiac Failure. 2015;21(4):355–361. doi: 10.1016/j.cardfail.2014.10.014</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Aimo A, Vergaro G, Passino C, et al. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis. JACC. Heart Failure. 2017;5(4):280–286. doi: 10.1016/j.jchf.2016.09.010</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Prokopova LV, Sitnikova MYu, Dorofeykov VV, et al. The place of non-routine HF-lEF in evaluation of one-year survival: where does the road go from “available prognosis”? Serdechnaya nedostatochnost. 2016;17(2):82–90. (In Russ.). [Прокопова Л.В., Ситникова М.Ю., Дорофейков В.В. и др. Место нерутинных биомаркеров СН-нФВ в оценке одногодичной выживаемости: куда ведет дорога от «доступного прогноза»? Сердечная недостаточность. 2016;17(2):82–90]. doi: 10.18087/rhfj.2016.2.2193</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Vukolova YuYu, Gubareva IV, Kiselyova GI, et al. Association of proprotein convertase subtilisine/kexin type 9 (PCSK9) with vessel atherosclerosis of carotid and coronary basins in patients with arterial hypertension. Aspirantskiy Vestnik Povolzhiya. 2019;5–6:54–59. (In Russ.). [Вуколова Ю.Ю., Губарева И.В., Киселева Г.И. и др. Связь пропротеина конвертазы субтилизин кексинового типа 9 с атеросклерозом сосудов каротидного и коронарного бассейнов у больных артериальной гипертонией. Аспирантский вестник Поволжья. 2019;5–6:54–59]. doi: 10.17816/2072-2354.2019.19.3.54-59</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble concentrations of the interleukin receptor family member ST2 and -blocker therapy in chronic heart failure. Circulation. Heart Failure. 2013;6(6):1206–1213. doi: 10.1161/CIRCHEARTFAILURE.113.000457</mixed-citation></ref></ref-list></back></article>
